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Familial intrahepatic cholestasis is a confusing group ofsyndromes. Fourforms aredefined and discussed
in detail ("arteriohepatic dysplasia," the Byler syndrome, theTHCA syndrome, and Norwegiancholestasis).
A comparison of the distinguishing characteristics of these syndromes demonstrates that they share many
features, including areflexia, retinal degeneration, and paucity of the intrahepatic bile ducts on biopsy.
Alternatively, some traits appear to be specific for a single syndrome: posterior embryotoxon and bony
anomalies forarteriohepatic dysplasia, the presence of an abnormal bile acid for the THCA syndrome, and
giant cell transformation for Norwegian cholestasis. These syndromes, although rare, merit complete
evaluation because, as nature's experiments in bile formation, they represent models ofcholestasis and may
provide clues to the understanding both ofotherforms ofcholestasis ofunknown etiology and ofthe normal
mechanisms of bile formation.
INTRODUCTION
Confusion Abounds
Cholestasis is a state of decreased hepatic bile formation, sometimes associated
with elevation in the serum bilirubin but always accompanied by an elevation in
serum bile acids [1]. Intrahepatic cholestasis has no extrahepatic, obstructive cause.
The term "intrahepatic cholestasis of childhood" has been used to describe patients
with prolonged cholestasis in whom no extrahepatic obstruction or atresia is found
[2]. Broad definitions such as this include a bewildering variety of patients who
demonstrate confusing differences in prognosis and response to therapy. Further
confusion arises when this group of patients is subdivided into disparate syndromes
which have been only incompletely characterized. This subdivision is still further
complicated by the fact that within each syndrome there exists a wide clinical
spectrum.
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The first step toward understanding these patients is to define clearly individual
syndromes. Such definitions should be detailed in order to provide the best possible
structure on which to base the diagnosis. On the other hand, these definitions must
also be flexible in order to include the wide clinical spectrum which can occur.
Diagnostic criteria which are too exacting only add to the confusion.
When such workable definitions of each syndrome have been established and
generally agreed upon, then these rare patients can be accurately compared from
institution to institution. Characteristics which are found in multiple, divergent
syndromes can then be presumed to be secondary, not of pathogenic significance.
Alternatively, characteristics unique to any one syndrome can be supposed to be
indicative of pathogenic mechanisms.
As will be seen, many of these cholestatic conditions in childhood are probably of
genetic etiology. As such, each presumably represents an "experiment in nature" on
the mechanisms of bile formation. Although the production of bile by the liver is
surely one of the body's most important tasks, its basic physiology is still very poorly
understood [3]. Therefore, each patient with familial intrahepatic cholestasis, no
matter how rare, deserves full evaluation, in hopes that a better understanding of
nature's "mistakes" will lead to understanding normality.
This paper will review four different types offamilial intrahepatic cholestasis. Two
types have been studied extensively here at Yale[4,5]. The data presented will include
that available in the literature but will be biased toward the Yale experience. The
other two have not been studied here but have been clearly described in the literature.
What's in a Name
A word about nomenclature is warranted. A disease cannot be adequately
described until its etiology is known. Pneumococcal pneumonia is a much more
informative name than chronic active hepatitis. All the syndromes discussed herein
are of unknown etiology. It seems preferable, therefore, as McKusick suggests [6], to
abandon attempts at adequate nomenclature until the specific defects are identified.
Instead we will use eponyms or abbreviated (and clearly incomplete) descriptions as
names.
THE SYNDROMES
"Arteriohepatic Dysplasia"
Patients with this condition were probably in the group described by Ahrens et al.
in 1951 [7]. Watson and Miller gave this syndrome the name arteriohepatic dysplasia
in 1973 [8]. Alagille and co-workers further described these patients, and the
syndrome is occasionally given Alagille's name [9]. Because Watson and Miller were
the first to report in English one of the major extrahepatic manifestations of this
syndrome, we will use the name arteriohepatic dysplasia, recognizing that it is
inadequate as a full description and has no pathogenic significance.
This syndrome is associated with cholestasis and usually jaundice in the neonatal
period (refer to Table 1). Laboratory tests reveal hyperbilirubinemia, although this is
not invariable, hypercholesterolemia with a Type II hyperlipoproteinemia, and
elevated alkaline phosphatase, SGOT, and 5' nucleotidase. The serum bile acids are
moderately elevated but there are no abnormal bile acids present. Thejaundice clears
in childhood, usually by age four, but milder cholestasis, as demonstrated by elevated
bile acids, alkaline phosphatase, and 5' nucleotidase, persists. In the adult, despite
normal bilirubin values, the BSP (sulfobromophthalein) Tm is markedly diminished
[4].
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TABLE I
Characteristics of Four Forms of Familial Intrahepatic Cholestasis
Arteriohepatic The Byler The THCA Norwegian
Dysplasia Syndrome Syndrome Cholestasis
Pattern of Cholestasis
Onset
Jaundice
Alkaline phosphatase
(nl < 75)
5' Nucleotidase
(nl < 10)
SGOT
(nl < 35)
Cholesterol
mg/dl
Bile acids
(nl < 4ug/ml)
BSP Tm
(nl 4.8-12.4)
Response to phenobarbital
Other Organ Involvement
Heart
Bones
Kidneys
Extremities
Neuro
Eye
Neonate 1-12 mo. Neonate Neonate
Clears Persistent May clear In episodic attacks
178-209
36-98
158-201
199-364
25-56
0.16, 2.3
0
PPS, +
Anomalies
Uric acid
4 Creatinine
clearance
Short fingers
Areflexia
Posterior embryo-
toxon
Retinal degener-
ation
293-440 t
15-28
96-140
134-141
87-130
'I1
Normal
Rickets
Normal
Clubbing
Areflexia
K-F rings,
late
t
Normal tDuring attacks
tDuring attacks I Cholate
t THCA
0
Normal
Clubbing
Retinal
degeneration
Leg edema
Areflexia
Liver biopsy
Bile ducts
Cholestasis
Giant cells
Cirrhosis
Presumed inheritance
II
0
0
Autosomal
dominant
Benign Outcome
May be4
+
0
+, late
Autosomal
recessive
Death in
childhood or
adolescence
I or prolif.
+ +
0 +
+ Possibly
Autosomal Autosomal
recessive recessive
Death by
age 2
Benign (?)
Key to table: 4= decreased, f = increased, 0 = reported to be absent, + reported to be present, - = not reported.
The remarkable feature of this syndrome is the multitude of associated anomalies
in other organs. The face is typically abnormal, with a broad forehead, small
maxillary region, and pointed chin [10]. The heart is involved, with markedly
attenuated peripheral pulmonary arteries plus a variety of other possible anomalies
[11]. There are characteristic anomalies of the bones, including butterfly vertebrae
[9], a pointed anterior process of Cl, shortened ulna, and decreased interpedicular
distances in the lumbar spine. The hands are small with foreshortened fingers. The
eyes are involved, with anterior chamber anomalies such as posterior embryotoxon.
In addition, some patients have choroidal degeneration with a variable degree of
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retinal involvement. Renal function may be impaired, with hyperuricemia and
decreased creatinine clearance. The patients are often areflexic and may have
minimal cerebral dysfunction.
The liver biopsy demonstrates cholestasis and a marked paucity ofintrahepatic bile
ducts. There is no progression to cirrhosis and the outcome appears to be benign. The
cholestasis does not improve on phenobarbital therapy, either in the infant or the
adult [12]. Transmission from one generation to the next in two instances [4,13]
suggests that this syndrome is inherited as an autosomal dominant. Watson and
Miller [8] reported a wide variability in clinical expression, as found in other
dominantly inherited syndromes.
The Byler Syndrome
A more progressive form of intrahepatic cholestasis was reported in 1965 in an
inbred Amish family named Byler [14]. Excellent descriptions of similarly affected
families have been published from points as divergent as Japan[15] and France[16],
as well as from Yale [5]. In this syndrome, the first symptom is often neonatal
malabsorption, followed within the first year of life byjaundice.(refer to Table 1). As
in arteriohepatic dysplasia, the liver function tests reflect cholestasis. As a rule, the
cholesterol is normal or low. Initially, thejaundice may come in attacks, precipitated
by intercurrent infections, but by childhood it is persistent. Serum bile acid levels are
high. Previous reports of elevated levels of lithocholate in the serum [17] have not
been substantiated and the bile acid pattern may be normal. The BSP Tm is markedly
decreased (less than 1 mg/min) [18].
Other organs are less commonly involved in this syndrome. The rickets frequently
observed [5,18] is presumably secondary to severe malabsorption of Vitamin D. The
patients may be severely retarded, both mentally and physically [18]. Kayser-
Fleischer rings have been observed in the Byler syndrome after many years of
cholestasis [19]. The patients also are areflexic and clubbing of the digits [18] is
prominent. The liver biopsy may show a relative paucity of intrahepatic bile ducts
initially [5], but later cirrhosis develops [18,19]. Phenobarbital therapy lowers the
serum bilirubin and decreases the pruritus, although it does not change the serum bile
acid levels [12,20]. The occurrence of this syndrome in sibships suggests inheritance
as an autosomal recessive [5,16,18]. Abnormalities of BSP transport in the fathers of
two cases [18] suggested that this test could be used to successfully demonstrate
heterozygotes but subsequent studies of another family have not confirmed this[21].
The prognosis is for death to occur in childhood or adolescence.
The THCA Syndrome
In 1975 Hanson et al. reported two siblings affected with a rapidly progressive
form of intrahepatic cholestasis which was associated with high levels of 3a,7a,12a-
trihydroxy-5,8-cholestan-26-oic acid (THCA) in serum and bile [22]. Jaundice
appears in the neonatal period in the THCA syndrome (Table 1). The bilirubin and
alkaline phosphatase are elevated but the cholesterol is normal. Total serum bile
acids are elevated but the cholic acid level is low, with instead a peakwhich migrates
late in the usual gas chromatographic analysis and is identical to THCA. In one case
jaundice improved coincident with cholestyramine therapy [22,23].
Involvement of other organs is not prominent. Growth retardation is present.
Retinal degeneration was described in one case [23]. Rickets has been reported. The
liver biopsy demonstrates paucity of the intrahepatic bile ducts, with progression to
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cirrhosis [22]. Phenobarbital has not been effective. The occurrence in sibships
suggests autosomal recessive inheritance [22,23], although a defect in presumed
heterozygotes has not been detected. Death has occurred by age two in the patients
reported thus far [22,23].
Norwegian Cholestasis
In 1968 Aagenaes et al. [24] reported a series of patients with intrahepatic
cholestasis from Norway. The patients reported by Sharp and Krivit in 1971 [25] with
a similar syndrome were also of Norwegian extraction.
Jaundice occurs in the neonatal period (Table 1). It clears in early childhood but
recurs intermittently throughout life, not necessarily in response to insults such as
infection or pregnancy. During attacks, the liver function tests are compatible with
cholestasis (elevated bilirubin, alkaline phosphatase, cholesterol, and triglycerides).
The serum bile acids are elevated but the pattern is normal [10,25].
The most striking finding in this syndrome is profound lymphedema of the legs
which begins either in childhood or before puberty. Although the jaundice clears
between attacks, the lymphedema is persistent. The patients have growth retardation
during attacks, but there is catch up growth and adults are ofnormal height. Rickets
may be present after prolonged cholestasis and attendant malabsorption. Areflexia
has been reported in this syndrome.
Liver biopsy may demonstrate either a paucity of intrahepatic bile ducts or some
degree of ductular proliferation. The striking biopsy finding in infants with this
syndrome is pronounced giant cell transformation ofthe hepatocytes [26]. Cirrhosis
has been reported in adults with the syndrome. The results of phenobarbital therapy
have not been reported. The occurrence of the syndrome in sibships suggests
autosomal recessive inheritance, although again an abnormality has not been
detected in presumed heterozygotes. Since the introduction of Vitamin K therapy
these patients no longer die of hemorrhage ininfancy and maylive normallife spans,
although cirrhosis has been reported in some.
Others
Limiting this discussion to these four syndromes excludes several others which
might have been included. There exist at least two other types of familial liver
diseases of unknown etiology which present in infancy [27,28]. In these syndromes
cholestasis is not prominent, so they were not discussed. There are two other well-
recognized syndromes of intrahepatic cholestasis: benign recurrent cholestasis [29]
and intrahepatic cholestasis of pregnancy [30]. Because these syndromes usually,
although not invariably, present after puberty and because they are not generally
considered familial-although familial instances have been reported-these were also
excluded from this discussion.
DIFFERENTIAL DIAGNOSIS
The four syndromes under consideration are compared inTable 1. Two are benign
in outcome (arteriohepatic dysplasia and Norwegian cholestasis) and two progress to
death (the Byler and THCA syndromes). The age of onset of these syndromes is
usually the neonatal period, although the Byler syndrome may not present until as
late as age 12 months. All four syndromes demonstrate chemical cholestasis, with
elevation in serum bile acids and alkaline phosphatase. Hyperbilirubinemia is usual
although not invariable. Of interest is the contrast observed between the SGOT and
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5' nucleotidase in the cases here at Yale. The Byler syndrome patients have more
severe hepatocellular disease (progressing to cirrhosis) and more severe cholestasis
but have lower SGOT's and 5' nucleotidases than patients with arteriohepatic
dysplasia. The serum cholesterol is also helpful differentially: in the "benign"
syndromes it is high, whereas in the more progressive syndromes it is normal or low.
BSP infusion studies have been used in a variety of clinical situations to assess the
capacity of the liver to excrete BSP [31], an organic anion which is metabolized in a
fashion similar to bilirubin. A nonspecific decrease in the BSP Tm can be seen in a
variety of liver diseases and very low levels are found in the Dubin-Johnson
syndrome [32]. Values in this low range are also seen in arteriohepatic dysplasia and
in the Byler syndrome. The BSP Tm can also be moderately low in benign recurrent
cholestasis, although it returns toward normal between attacks [33].
By definition, the serum bile acids are elevated in all of these cholestatic syn-
dromes. The only specific abnormality is in the THCA syndrome, where the total
cholate level is low and instead there is an elevated THCA level. THCA is a major
bile acid in alligators and a precursor of cholic acid in humans. Abnormal precursor
bile acids, both THCA and DHCA, are also seen in patients with Zellweger's
syndrome (the cerebro-hepato-renal syndrome), a disease of multiple anomalies,
including infantile cirrhosis [34,35].
Multiple organ involvement can be seen in several of the familial intrahepatic
cholestatic syndromes, although this is the particular hallmark of arteriohepatic
dysplasia. In this condition, posterior embryotoxon has been seen in all patients and
may be quite specific for this disease. Variable degrees of choroidal sclerosis and
retinal degeneration are found, and it is interesting that retinal involvement is also
reported in one patient with the THCA syndrome. K-F rings have been reported late
in the course of the Byler syndrome but are in no wayspecific for this disease. Absent
or markedly decreased reflexes have been reported in three of the four syndromes
discussed. Finally, examination of the extremities in these syndromes can be very
rewarding. Patients with both of the "progressive" conditions (Byler and THCA)
have clubbing, whereas patients with arteriohepatic dysplasia have small hands with
foreshortened fingers and patients with Norwegian cholestasis have lymphedema.
Improvement in cholestasis during phenobarbital therapy has been reported both
in adults and children [36]. The hyperbilirubinemia of the Crigler-Najjar syndrome
can be successfully treated with this drug, which delineates two distinct subgroups,
one which responds to phenobarbital with a decrease in serum bilirubin, and one
which does not [37]. Phenobarbital was initially felt to be useful in the treatment of
familial intrahepatic cholestasis [38,39,40], although it is clear that not all patients
respond [39]. We have demonstrated a decrease in serum bilirubin on phenobarbital
in patients with the Byler syndrome. No change was seen in the patient with the
milder condition, arteriohepatic dysplasia [12], and none reported in the THCA
syndrome [22].
The liver biopsy may be very helpful in the diagnosis of these syndromes [41], but
only when taken in the clinical context. Table 1 shows that a p.aucity of intrahepatic
bile ducts (Fig. 1) may be found in any of the syndromes under discussion, but this is
a nonspecific finding and should not be used as the sole diagnostic criteria for any
syndrome. Thirteen children with paucity or absence of the intrahepatic bile ducts
have been evaluated at Yale in the past 30 years (Table 2). The most common cause of
this finding was arteriohepatic dysplasia, with extrahepatic atresia the second most
common cause. Several of these patients had syndromes which did not readily fall
into any specific syndrome.
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FIG. 1. Portal triad from a patient with arteriohepatic dysplasia. A large vein is seen, as well as several smaller
arterioles. No duct is present. This appearance could be found in any of the four conditions discussed.
DISCUSSION
An analysis of Table 1 demonstrates that several of the characteristics of these
syndromes occur in more than one syndrome. It would seem safe to assume,
therefore, that these characteristics are nonspecific and are in some waysecondary to
the underlying disorder. For instance, it is not surprising that clubbing of the
extremities has been reported in the two more progressive syndromes, as thisfinding
is common in cirrhosis. Similarly, a decrease in the BSP Tm has been reported in
many forms of liver disease and is found both in arteriohepatic dysplasia and in the
Byler syndrome. As discussed above, a decrease or absence of the intrahepatic bile
ducts is nonspecific. It would be of interest to speculate that perhaps this decrease in
bile ducts is secondary to the cholestasis, the decreased hepatic bile formation. It is
unlikely to be the cause of the cholestasis as it is quite nonspecific for any one
syndrome.
The table reveals two new associations with infantile liverdisease and/or cholesta-
sis. The first is hypo or areflexia, a finding in three out ofthe four syndromes. This
association has previously been reported in children with unclassified progressive
liver disease [42] but its etiology is obscure. The second new association is that of
retinal degeneration, a finding observed in some of our patients with arteriohepatic
TABLE 2
Paucity of Intrahepatic bile ducts on biopsy.
Presumed clinical diagnosis in all children
seen at Yale with this finding, 1948-1978.
Arteriohepatic Dysplasia 5
The Byler Syndrome 2
Extrahepatic Obstruction 3
Other (? Diagnosis) 3
Total 13
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dysplasia and in one patient with the THCA syndrome. The etiology ofthis finding is
also unknown but it appears to be nonspecific.
Table 1 also demonstrates that few characteristics are specific or pathognomonic
for any one syndrome. Bony anomalies and posterior embryotoxon have been found
only in arteriohepatic dysplasia, not in the Byler syndrome, and have not been
reported to occur in either of the other two syndromes. A specific abnormality in
serum and bile acids has been demonstrated only in the THCA syndrome [22]. This
abnormal bile acid is not present in arteriohepatic dysplasia or in the Byler
syndrome, both of which show elevated levels ofcholic acid in serum, unlike findings
in the THCA syndrome. Giant cell transformation of the liver is seen only in
Norwegian cholestasis. This finding occurs in other types of neonatal jaundice, but
not in any ofthe otherforms offamilial intrahepatic cholestasis. These characteristics
which are specific for only one syndrome may perhaps provide clues to understand-
ing the underlying pathogenesis.
Speculation
It now seems clear that all four syndromes under discussion have a genetic
etiology. The pathogenic mechanism underlying each syndrome remains an enigma,
however. It is tempting to speculate that these are all diseases of bile formation and
that a better understanding of the pathogenesis of these syndromes will lead to a
better understanding of the normal mechanisms of bile formation.
Based on the foregoing discussion, some speculations can be made about the
pathogenesis of each of these syndromes. Arteriohepatic dysplasia is clearly a multi-
organ disease. This catholic organ involvement suggests a defect in connective tissue
and one might suppose that a generalized defect in microfilament function could
result in a decrease in bile formation [43] as well as other organ involvement. The
Byler syndrome is restricted to the liver, and seems to represent a severe, generalized
defect in hepatic excretory function, perhaps involving some as yet undefined
common excretory enzyme. The THCA syndrome is characterized by the presence of
an abnormal bile acid in serum and bile. It is presumed that this syndrome represents
an inborn error of bile acid metabolism, with a block in the major biosynthetic
pathway to cholic acid at the cleavage of the cholesterol side chain [44]. It is unclear
why this defect results in liver disease but one might postulate that the abnormal C27
bile acid is in some way toxic to the liver, perhaps to the canalicular membrane.
Lithocholic acid, a normally occurring secondary bile acid, causes cholestasis when
infused into animals [45]. Feeding this bile acid to pregnant rats results in a
cholestatic syndrome in the infant and it has been suggested that this cholestasis is
secondary to a decrease in Na+,K+-ATPase activity in the liver plasma membranes
[46]. Such a model is interesting and may be related to the THCA syndrome.
Norwegian cholestasis is characterized bylymphedema ofthe legs and one author has
suggested that the hepatic abnormality may also be secondary to abnormal lymph.
These kinds of speculation can be further extended to other types of cholestatic
syndromes, for instance benign recurrent cholestasis, intrahepatic cholestasis of
pregnancy, and perhaps even primary biliary cirrhosis. It is possible that information
gained from study of the familial intrahepaticcholestatic syndromes may be ofuse in
understanding and treating these other types of cholestasis of unknown etiology.
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